Nagaya Tadanobu, Nakamura Yuko, Sato Kazuhide, Harada Toshiko, Choyke Peter L, Kobayashi Hisataka
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States.
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, Bethesda, MD, 20892 United States.
J Control Release. 2016 Jun 28;232:1-8. doi: 10.1016/j.jconrel.2016.04.003. Epub 2016 Apr 5.
Near infrared photoimmunotherapy (NIR-PIT), a targeted cancer therapy which uses an antibody-photo absorber conjugate (APC) and near infrared light exposure, dramatically improves nano-drug delivery into treated tumor beds due to enhanced vascular permeability. We investigated the micro-distribution of APCs in a variety of NIR-PIT treated tumors. Either cetuximab (cet) or trastuzumab (tra) conjugated with IR700 (cet-tra-IR700) was administered, as appropriate, to each mouse model of tumor. Tumor-bearing mice implanted with A431-GFP, MDAMB468-GFP, 3T3Her2-GFP or N87-GFP were separated into 5 groups: group 1=no treatment; group 2=cet-tra-IR700 i.v., no light exposure; group 3=cet-tra-IR700 i.v., NIR light exposure; group 4=cet-tra-IR700 i.v. and additional cet-tra-IR700 i.v. at 24h but no light exposure; group 5=cet-tra-IR700 i.v., NIR light exposure and additional cet-tra-IR700 i.v. immediately after NIR but no additional NIR light exposure. In vivo, ex vivo and microscopic fluorescence imaging was performed. Fluorescence from the surface of the tumor (s-tumor) was compared to fluorescence from deeper areas of the tumor (d-tumor). In general, there was no significant difference in the fluorescence intensity of GFP in the tumors among all groups, however the highest IR700 fluorescence intensity was consistently shown in group 5 tumors due to added APC after NIR-PIT. Fluorescence microscopy in all tumor types demonstrated that GFP relative fluorescence intensity (RFI) in s-tumor was significantly lower in group 3 and 5 (NIR-PIT groups) than in group 1, 2, and 4 (no NIR-PIT) yet there was no significant difference in d-tumor RFI among all groups. IR700 fluorescent RFI in the d-tumor was highest in group 5 (NIR-PIT+additional APC) compared to the other groups. Cell killing after NIR-PIT was primarily on the surface, however, APCs administered immediately after NIR-PIT penetrated deeper into tissue resulting in improved cell killing after a 2nd NIR-PIT session. This phenomenon is explained by increased vascular permeability immediately after NIR-PIT.
近红外光免疫疗法(NIR-PIT)是一种靶向癌症治疗方法,它使用抗体-光吸收剂共轭物(APC)并进行近红外光照射,由于血管通透性增强,可显著改善纳米药物向治疗后的肿瘤床的递送。我们研究了APC在多种经NIR-PIT治疗的肿瘤中的微观分布。将与IR700共轭的西妥昔单抗(cet)或曲妥珠单抗(tra)(cet-tra-IR700)酌情施用于每种肿瘤小鼠模型。将植入A431-GFP、MDAMB468-GFP、3T3Her2-GFP或N87-GFP的荷瘤小鼠分为5组:第1组=不治疗;第2组=静脉注射cet-tra-IR700,不进行光照;第3组=静脉注射cet-tra-IR700,进行近红外光照射;第4组=静脉注射cet-tra-IR700,并在24小时后额外静脉注射cet-tra-IR700,但不进行光照;第5组=静脉注射cet-tra-IR700,进行近红外光照射,并在近红外光照射后立即额外静脉注射cet-tra-IR700,但不进行额外的近红外光照射。进行了体内、体外和显微镜荧光成像。将肿瘤表面的荧光(s-肿瘤)与肿瘤深部区域的荧光(d-肿瘤)进行比较。一般来说,所有组肿瘤中GFP的荧光强度没有显著差异,然而,由于在NIR-PIT后添加了APC,第5组肿瘤中IR700荧光强度始终最高。所有肿瘤类型的荧光显微镜检查表明,第3组和第5组(NIR-PIT组)肿瘤表面的GFP相对荧光强度(RFI)显著低于第1组、第2组和第4组(无NIR-PIT组),但所有组肿瘤深部的RFI没有显著差异。与其他组相比,第5组(NIR-PIT+额外APC)肿瘤深部的IR700荧光RFI最高。NIR-PIT后的细胞杀伤主要发生在表面,然而,在NIR-PIT后立即施用的APC更深地渗透到组织中,导致在第二次NIR-PIT疗程后细胞杀伤得到改善。这种现象可以用NIR-PIT后血管通透性增加来解释。